Trials / Unknown
UnknownNCT06193278
Individual Neuromodulation for PDS
Personalized Neuromodulation Treatment for Parkinson's Syndrome
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Parkinsonian Syndromes (PDS) with predominant motor dysfunction include progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal degeneration (CBD). Current treatment options for PDS are extremely limited due to the less understanding of disease pathophysiology and lack of therapeutic targets. Combining the results of previous studies and our group's previous research, sixty qualified PDS patients would be enrolled to conduct a prospective single-center randomized sham controlled clinical trial to verify the new therapeutic options that can improve symptoms and effectively slow the progression of the disease.
Conditions
- Neuromodulation
- Parkinsonian Syndromes
- Transcranial Magnetic Stimulation
- Transcranial Direct Current Stimulation
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Neuromodulation | Noninvasive brain stimulation (NIBS) includes a variety of noninvasive neuromodulation techniques such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (TDCS), and so on. Theta burst stimulation(TBS) is a new form of excitatory or inhibitory rTMS treatment that is less time-consuming and more effective than traditional rTMS in a single treatment session. |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2025-05-31
- Completion
- 2025-06-30
- First posted
- 2024-01-05
- Last updated
- 2024-01-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06193278. Inclusion in this directory is not an endorsement.